Asundexian May Offer Safer Stroke Prevention in AF Patients New to Blood Thinners: OCEANIC-AF Analysis
USA: A recent subgroup analysis from the OCEANIC-AF randomized clinical trial highlights that asundexian, a novel oral Factor XIa inhibitor, may offer a favorable balance of safety and efficacy compared to apixaban in patients with atrial fibrillation (AF), especially those who were naive to oral anticoagulant (OAC) therapy.
"In these OAC-naive patients, asundexian was associated with a slight increase in stroke rates but demonstrated a lower risk of bleeding than apixaban, suggesting its potential as a safer alternative in select AF populations," the researchers reported in JAMA Cardiology.
In patients with atrial fibrillation, oral anticoagulants play a crucial role in reducing the risk of stroke. John H. Alexander, Duke University Medical Center, Durham, North Carolina, and colleagues aimed to explore whether the effectiveness and safety of a new OAC vary depending on a patient’s prior exposure to anticoagulant therapy.
For this purpose, the researchers conducted a subgroup analysis of the OCEANIC-AF trial, categorizing patients with atrial fibrillation as either OAC naive (≤6 weeks of prior use) or OAC experienced (>6 weeks). Asundexian, a novel Factor XIa inhibitor, was compared to apixaban across these groups. The trial involved participants from 1035 sites across 38 countries.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.